Abstract
We evaluated the efficacy, safety, and usefulness of cefdinir (CFDN), a new oral cephem, in bacterial pneumonia by the multicenter double-blind comparative method using cefaclor (CCL) as a control drug. The dosage was 100 mg of CFDN t.i.d. and 500 mg of CCL t.i.d. for 14 days in principle. 1. The clinical efficacy rate judged by committee was 88.9% for CFDN and 89.9% for CCL. There was no significant difference between the two drugs. 2. In the evaluation of bacteriological effect, the eradication rate was 86.7% and 88.9% in patients given CFDN and CCL respectively. There was no significant difference between the two drugs. 3. There were no significant differences between the two drugs in the improvement rate of clinical symptoms and laboratory parameters. 4. The incidence of side effects was 4.9% in the CFDN group and 3.1% in the CCL group. The incidence of abnormal findings was 20.2% in the CFDN group and 29.5% in the CCL group. There were no significant differences between the two drugs in incidence of side effects or abnormal laboratory findings. 5. The usefulness rate was 83.8% for CFDN and 89.6% for CCL. There was no significant difference between the two drugs. The clinical efficacy, safety, and usefulness of CFDN 100mg t.i.d. were as high as those of CCL 500mg t. i. d. It is concluded that CFDN is an oral antibiotic which is clinically useful in the treatment of bacterial pneumonia.
Original language | English |
---|---|
Pages (from-to) | 634-659 |
Number of pages | 26 |
Journal | Chemotherapy |
Volume | 37 |
DOIs | |
Publication status | Published - 1989 |
Externally published | Yes |
Keywords
- Cefdinir
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology